ArticleCureus2026
Clinical Safety Profile of Bruton's Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukaemia: A Real-World Ambispective Study From India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic lymphocytic leukaemia (CLL) is the most common leukaemia among adults in Western regions, while India reports comparatively lower incidence rates. Bruton's tyrosine kinase (BTK) inhibitors, particularly ibrutinib and acalabrutinib, have reshaped CLL therapy by blocking B-cell receptor signalling pathways essential for malignant B-cell survival.
objectiveGiven the increasing use of BTK inhibitors in routine practice and the limited real-world Indian data, this study evaluates the clinico-safety profile of BTK inhibitors and identifies predictors of response and progression in a pragmatic clinical setting. MATERIALS AND
methodsThis was a single-centre ambispective observational study conducted from June 2021 to June 2024 in patients diagnosed with CLL aged 18-70 years. The patients received ibrutinib (420 mg once daily) or acalabrutinib as per availability and physician decision.
resultsAmong the 93 patients included, most were male and younger than typical Western CLL cohorts. Hematologic recovery rates were high, with normalisation of haemoglobin, platelet count, and leukocyte count seen in the majority within four to seven months of therapy. The overall median progression-free survival (PFS) was 14 months.
conclusionBTK inhibitors have significantly improved therapeutic outcomes in CLL. Both ibrutinib and acalabrutinib demonstrated meaningful hematologic responses and prolonged disease control. Acalabrutinib showed superior tolerability and better treatment adherence. Expanding access to genomic testing and improving drug availability will be essential to optimise CLL care in India.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.